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Abstract
The cochlear implant (CI) represents, for almost 25 years now, the gold
standard in the treatment of children born deaf and for postlingually
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deafened adults. These devices thus constitute the greatest success
story in the field of ‘neurobionic’ prostheses. Their (now routine) fitting
in adults, and especially in young children and even babies, places ex- 1 Department of
Otolaryngology, Goethe acting demands on these implants, particularly with regard to the
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biocompatibility of a CI’s surface components. Furthermore, certain
parts of the implant face considerable mechanical challenges, such as
theneedfortheelectrodearraytobeflexibleandresistanttobreakage,
and for the implant casing to be able to withstand external forces.
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Astheseimplantsareintheimmediatevicinityofthemiddle-earmucosa
and of the junction to the perilymph of the cochlea, the risk exists – at
least in principle – that bacteria may spread along the electrode array
intothecochlea.Thewide-rangingrequirementsmadeoftheCIinterms
of biocompatibility and the electrode mechanism mean that there is
still further scope – despite the fact that CIs are already technically
highly sophisticated – for ongoing improvements to the properties of
these implants and their constituent materials, thus enhancing the ef-
fectiveness of these devices.
This paper will therefore discuss fundamental material aspects of CIs
as well as the potential for their future development.
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1 The cochlear implant
1.1 Clinical requirements
The chief clinical requirements that have to be fulfilled
by a cochlear implant derive from the main functional
principle of the implant: the differential, site-specific
transferofchargetotheauditorynerveandthetonotopic
hearing sensation that this generates. The CI systems
currently available have developed largely out of cardiac
pacemaker technology. In this regard it has proved pos-
sible to draw on broad empirical experience, not only in
relation to the use of suitable materials (silicone, ceram-
ics,titaniumandplatinum),butalsointermsofbenefiting
fromthealreadyexistingproductiontechnology(Figure1).
In the early phase when CIs were first being introduced,
this meant that even at that initial stage these implants
had good biocompatibility [1]. Ensuring the long-term
stability and long-term function of CIs is one of the main
clinical needs within the requirement profile for these
implants. The reasons for this are twofold: the early age
at implantation, and the high average life expectancy of
therecipients,whocontinuetoreceivetechnicalinterven-
tion into their senior years. The intention, therefore, is to
give implants a functional life of several decades. The
choice of implant materialsis thus of crucialsignificance
– the aim being, as far as possible, to prevent the need
for revision surgery or for operations to replace the im-
plant, as this delays auditory rehabilitation and places a
strain on the recipient.
Figure 1: The implantable portion of the cochlear implant: (1)
Transmitter coil in a silicone sheath; (2): Electronics enclosed
in a titanium casing; (3): Electrode with platinum contacts in
a silicone array; (4): Cochleostomy site; (5): Silicone cable in
the middle-ear/mastoid region.
As well as meeting the material requirements geared to
long-term stability, the materials used must (as far as
possible)behypoallergenic.Inadditiontotheirbiological
compatibility, the long-term technical integrity of the im-
plants is therefore a further important necessity. The
clinical demands made of a CI were described as follows
in 1992 by E. Lehnhardt (modified after [2]):
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ically tolerated);
• The insertion of the electrode array should not cause
any additional damage;
• Thesurgicaltechniqueusedshouldbeasnon-invasive
as possible;
• There needs to be efficient, non-damaging electrical
stimulationoftheauditorynerveonasustainedbasis;
• There must be no increased risk of infection caused
by the implant and by the access route to the fluid-
filled spaces of the cochlea.
1.2 Clinical provision: status
At present, some 2,000 cochlear implants are fitted in
Germany every year. By way of comparison, around
66,000cardiacpacemakersareimplantedthereannually
[3]. The technical execution of the surgical procedure is
now standard medical practice. Alongside routine unilat-
eral implantation, bilateral CI fitting has become an es-
tablishedapproachinrecentyears,whichmakespossible
a considerable improvement in both spatial hearing and
speechunderstandingforCIusers[4].Bilateralimplanta-
tion,especiallyamongrecipientsfittedinearlychildhood,
has now become virtually the standard therapy for deaf-
born children.
The large incision (“Hannover C-incision”, Figure 2)
formerlyusedhasnowbeenabandonedbymostsurgeons
in favour of considerably smaller, primarily retroauricular
access routes (Figure 3) [5]. This has made for a consid-
erablereductionintherateofpostoperativeinfection[6],
[7]. A possible cause of this could be the fact that, where
thesmallerincisionisused,thisallowsthesuperiorblood
supply to the skin flap to be preserved [8]. The surgical
procedure generally involves mastoidectomy, posterior
tympanotomy, and the drilling of a cochleostomy in order
toinserttheintracochlearelectrodearray.Manysurgeons
createabonyrecessintheboneoftheskull,whichserves
to accommodate the implant(i.e. as an implantbed) and
thus provide protection against undesired mobilization
of the device. A connecting tunnel between the implant
bed and the mastoid is often also used, which allows
protection of the electrodes at the point where they exit
the implant, as well as serving to additionally fix the
device in place within the bone. The use of auxiliary ma-
terials [9], [10], [11] to hold the implant in position (such
assutures,osteosyntheticmaterial,bonecement,Dacron
suturesandtitaniumclips)hasthereforebeendiscontin-
ued by many surgeons as the implant can be adequately
secured by modifying the surgical technique accordingly
(i.e. by creating a bony implant bed and bony projections
in the area of the mastoid in order to protect the elec-
trode). The main reason for this change in practices lies
in the observation that, viewed in the long term, some of
theauxiliarymaterialsusedshowinsufficientbiocompat-
ibility or have led to local irritation. These include the
formation of cochleastomas following the use of Dacron
sutures for securing the electrode array in the rear wall
oftheearcanal.Overall,boththesurgicalprocedureand
thelong-termstabilityofthematerialsusedhaveresulted
inahighdegreeoftechnicalreliabilityandsurgicalsafety.
Figure 2: Preoperative marking of the incision line for the
“Hannover C” incisionformerlyused, showing the large wound
surface that results.
Figure 3: Smaller, retroauricular incision in use today (left ear,
dummy implant).
2 General material requirements
for a cochlear implant
A cochlear implant, unlike many other implants used in
human applications, has a number of very different re-
quirements to fulfil. These include mechanical stability
and charge transfer to the auditory nerve, as well as
biocompatibility and long-term stability.
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Themechanicalrequirementsforacochlearimplantvary
greatly with regard to the individual components. The
implant’soutercasingneedstobeastableandfluid-tight
enclosure that securely houses the electronics. This is a
not insignificant aspect in terms of ensuring the device’s
long-term functioning. Important materials that have
found application over the years include titanium and
ceramics,eachofwhichcombinesanumberofbeneficial
properties. Although ceramic materials have high resis-
tance to breakage, almost all CI manufacturers now fa-
vourtitaniuminsteadforhousingtheimplant’selectronic
components.Thisisbecauseceramicshaveprovedprone
to a lack of leak-tightness, leading to implant failure, and
because their mechanical resistance to external forces
(such as impact trauma to the head) is poorer than that
of titanium. Moreover, the most important parts of the
implant casing are coated with a layer of silicone
(Figure 1). In a 2002 analysis (carried out at Hannover
Medical School) of the reasons for removal of CIs manu-
factured by Advanced Bionics and Cochlear, a technical
defect was identified in 97 cases (i.e. 66.4% of these
explantations), of which 13 were attributable to a lack of
leak-tightness and a further 54 to impact damage [12].
The investigations carried out during this study related
to the augmentationof the standard thatgoverns“active
implantable medical devices” specifically for cochlear
CIs. In this connection, proposals for a uniform reporting
standardtobefollowedbymanufacturersandimplanting
centres in the event of implant failure have been drawn
up by Battmer et al. [13].
Thesecondpartoftheimplant,theelectrodearray,needs
to exhibit not only great flexibility but also long-term
mechanicalstabilityif it is not to give rise to cablebreaks
in thebendofthearray, orto a lackofleak-tightness(the
latter being caused by short-circuiting). Modern CI elec-
trodes usually consist of a silicone carrier material in
which the platinum contacts and the input wires (plati-
num-iridium 90/10 with insulating Teflon coating) are
embedded.
CertainCIelectrodesplacecomplexdemandsonmechan-
ical geometry, as the electrode bodies are preformed;
example include the Nucleus Contour system (Cochlear
Ltd.) or the Helix electrode from Advanced Bionics. The
bent shape of the electrode (Figure 4) is designed to re-
ducethedistancebetweentheelectrodeandtheneuron-
al cells in the modiolus, thus leading to focused stimula-
tion.Elasticmaterialsareabletoreduceinsertiontrauma,
althoughtheelectrodemusthavethenecessarystiffness
to ensure it can be inserted atraumatically, and be posi-
tioned safely and reproducibly within the cochlea. Coch-
lear’s Contour electrode has an elasticity of 4.8x108 Pa
at the tip and 4.0x108 Pa at the base. The side adjacent
to the modiolus is somewhat more elastic than the outer
side. The Nucleus straight electrode, however, has lower
flexural rigidity at the tip. The elasticity module at the tip
is 1.8x108 Pa, whereas the flexural rigidity of the base
(4.9x108 Pa) [14], [15] is similar to that of the Contour
electrode. Electrode stiffness is thus determined less by
thecarriermaterial(i.e.silicone,withanelasticitymodule
of 4.5x105 Pa) and more (indeed, chiefly) by the internal
Pt/Ir wires, whose geometric configuration is the main
influence on the electrode’s mechanical properties [15].
It is frictional forces that play the most significant role in
terms of electrode insertion [16], [17]. Comparative
studies have revealed Contour electrodes and the Nucle-
usstraightelectrodetohavesimilarfrictionalcoefficients
onthemodiolarside,withtheContourelectrodeexhibiting
considerably lower frictional coefficients on the lateral
side [18].
Figure4:Viewofpreformedelectrodewithmodifiedtip(Softip
®,
Cochlear Ltd).
The choice of material plays a major part, especially with
regard to the development of new electrode designs, as
heretheelectrodeisrequiredtomeetotherrequirements
in terms of its mechanical properties. Examples include
electrodeswithasofttipandlowcontactpressureonthe
basilar membrane and the outer wall of the cochlea
(Softip
®, Cochlear Ltd., Figure 4) [19], as well as the de-
velopment of new access routes to the cochlea, as for
example with the endosteal electrode [20], [21]. Here,
theuseofnovelcarriermaterials(suchasnewpolymers)
couldleadtotheelectrodes’mechanicalpropertiesbeing
optimized [22]. Furthermore, the literature contains indi-
vidual reports on applications in animal experiments in-
volving electrode arrays, surface-coated with polymers,
whichbringaboutalterationsintheelectrodemechanism
[23], [24].
2.2 Biological requirements
With regard to the middle-ear region, the biological re-
quirements for cochlear implant electrode arrays relate
tothepossibilityofcontactwithbacteriaandthepotential
spread of pathogens along the electrode array into the
recipient’s inner ear [25]. It is important to ensure that
the cochleostomy is well-sealed and to prevent a sheath
of connective tissue forming around the electrode array
(Figure5)[26].Thefactthatpathogenscomeintocontact
3/22 GMS Current Topics in Otorhinolaryngology - Head and Neck Surgery 2009, Vol. 8, ISSN 1865-1011
Stöver et al.: Biomaterials in cochlear implantswith the electrode surface relatively frequently in the
middle-ear region means a risk exists that a biofilm will
form or, in extreme cases, that bacteria will spread from
the middle ear into the inner ear [27], [28], [29] or the
cerebrospinal fluid, and that meningitis may occur. It is
thus especially important to securely seal the coch-
leostomy (Figure 6) [30], [31].
Figure 5: Histological section through the cochlea of a guinea
pig showing formation of new connective tissue and bone in
the area of the scala tympani (EK: electrode channel; scala
vestibuli (Sc. V.); scala media (Sc. M.); RK: Rosenthal channel,
BDG: connective tissue, K: bone).
Figure 6: View of the cochleostomy during the insertion of a
cochlear implant electrode.
2.3 Electrical requirements
The chief function of the cochlear implant involves facili-
tating charge transfer from the electrode array to the
auditorynerveandthehearingsensationthatthisgener-
ates. At present, all CI manufacturers use platinum con-
tacts in electrode production [2]. Moreover, iridium oxide
coatingshavebeeninvestigatedincertainstudies,which
showed beneficial effects in terms of what happens to
impedance following implantation [32], [33].
The demands placed on electrode contacts are highly
exacting with regard to the potential functional life of
implants (>20 years). It is essential to avoid corrosion
[34]andtopreventtheelectrodecontactsbeingdamaged
or destroyed. Long-term stimulation of neural tissue in-
volvingachargedensityof<30µC/cm
-2geometric/phase
is generally regarded as safe [35], provided the stimula-
tion is pulsatile in nature and the electrode surface is
relativelylarge[2].Thisvalueiswellbelowthoseatwhich
electrochemical responses can be expected. With plati-
num electrodes, gas is observed to form at values of
300 µC/cm
-2 geometric/phase and above, owing to elec-
trochemical changes [36]. If neural damage occurs even
at low values, this should be interpreted as the result of
electrical stimulation of the neural structures and not as
beingattributabletonoxiouschemicalsubstancesgener-
ated by undesired electrochemical responses [2]. Corro-
sion of the platinum can be observed at 500 µs/pulse
and above, or at or above a current density of 2 mA/mm
2
[37]. These values, too, are well below the parameters
used in clinical practice (namely 0.9 mA and
25 µs/phase). Platinum is thus an extremely safe mater-
ialforhumanapplicationsinvolvingcochlearimplantation.
2.4 Long-term stability
Alongside mechanical considerations (such as the need
to prevent electrode breakage and thus short-circuiting),
density-related aspects play a particularly important role
in determining implants’ long-term stability. Implants
sometimes fail a number of years after implantation, al-
though it is most likely to happen within the first two
years.Forexample,astudybyMaureretal.[38],involving
three different implant types, revealed the cumulative
survival rate to be 93.2% two years after implantation
and 92.7% five years post-implantation. These findings
show that the technical integrity of implants in present-
day use has reached a high level but still has scope for
further improvement.
3 Currently used materials and
their properties
3.1 Overview
The use of cochlear implants involves the following ma-
terialscomingintocontactwiththehumanbody:silicone,
platinum,titaniumandceramics.Platinumisusedasthe
electrode contact. For the Teflon-coated wires between
the receiver/stimulator and the electrode contacts, plat-
inum/iridium 90/10 is used. The wires are embedded in
silicone, and thus do not come into contact with human
tissue.Theelectronicswithintheimplantbodyarehoused
inatightlysealedcasingwhich–dependingonmanufac-
turer and implant series – is made of either ceramics or
titanium. The materials that come into contact with the
human body are dealt with more fully below.
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Silicones are polymers that are built around a frame of
siliconandoxygenatoms,onwhichhydrocarbonradicals
(which, in the case of silicones used in medicine, are
usually methyl groups [39]), are often present. The indi-
vidual polymer chains may differ in length and in the de-
gree of crosslinking. Chain length and cross-linkage are
criticalindeterminingthephysicalpropertiesofsilicones
[40]. These materials have been used in medicine for
more than 60 years now [39].
Siliconesforuseinmedicineareregardedashavinggood
biostability [39]. Owing to their flexibility and stability,
thesematerialsareusedforvariousprostheses(including
blood vessels, finger joints, heart valves and prosthetic
outer ears) [41]. There are, however, indications that sil-
icones'propertieschangefollowingimplantation;inother
words, a kind of ‘ageing’ process sets in [42], [43]. Fur-
thermore, Leslie et al. [44] have been able to show that
theinternalenvironmentwithinthebodyalsoaffectsthis
process of deterioration in silicones. This means that sil-
icones, despite their excellent biocompatibility, still have
potential for improvement.
3.3 Platinum
Precious metals such as platinum are preferred as con-
tact materials where electricalstimulationis involved, as
they havelow chemicalreactivityandarehighlyresistant
to corrosion. However, even precious metals can, upon
electrical stimulation, partially dissolve or form unstable
surface films. The extent of these undesired effects de-
pends upon the density of the charge that is transmitted
during electrical stimulation and on the polarity of the
stimulus [45], [46]. Platinum is very well tolerated by the
bodyand,asitisrelativelysoftincomparisonwithiridium,
is easier to work with. Even after around 2,000 hours of
stimulation testing in animal experiments, and as much
as 10,000 hours of such testing in humans, no stimulus-
induced corrosion has been detected [34]. Platinum
thereforeconstitutesthebestelectrodematerialcurrently
available.
3.4 Titanium
Titanium is particularly suitable for applications in which
rigidity, low weight and high resistance to corrosion are
essential. Titanium is an inert and solid metal. Its use for
the casing of the receiver/stimulator has its origins in
experience with cardiac pacemaker technology. In order
to securely seal the pacemaker housing, a ceramic ma-
terial has been developed that bonds permanently to
both the metal of the wires and to the titanium of the
casing [35]. This became the standard technique for
sealingthepointwherethewiresexitthepacemakerand
was adopted in the development of certain cochlear im-
plants [47]. Where titanium is used as a casing material,
thereceivercoilmustbeplacedoutsidethecasing.Titani-
um is therefore the material most commonly used by
manufacturers for enclosing the electronic components
of CIs.
3.5 Ceramics
Ceramic materials are non-metallic composites that fre-
quently consist of a matrix made of a base material per-
meatedwithvariousothersubstances.Thematerialsthat
a given ceramic contains determine its subsequent
properties,asdoesthenatureoftheproductionprocess.
Ceramics used for technical applications are commonly
based on aluminium oxide (Al2O3).
Ceramicsareused(seesection4.4)forsealingthepoints
where the wires emerge from the implant casing. They
also find (or found) application as a casing material for
enclosing the electronic components. An advantage of
usingceramicmaterialsforthispurposeisthatthereceiv-
er coil can be placed within the casing, as ceramics do
not greatly affect signal transmission. However, the ma-
terial is more brittle than titanium and thus more prone
to breakage under significant mechanical stress
(Figure 7).
Figure 7: Cochlear implant with cracked casing (here, ceramic
casing) following application of mechanical force caused by
the wearer falling on the implant.
4 Clinical application of
biomaterials used
4.1 Allergic reaction/material
incompatibility
The literature contains only isolated instances in which
ademonstrableallergicreactionorintolerancetosilicone
(where it is the principal material in cochlear implants)
is described [48], [49], [50]. These cases, however, have
prompted the provision of test kits in which material
samples are made available by the manufacturers in
laminar or rod form for implantation at a site (such as
the forearm) that is well away from the ear (Figure 8).
Thisprocedureallowsindividualizedcompatibilitytesting
– involving an observation period of around six weeks –
intended to rule out allergic responses to the CI material
which is to be implanted.
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of the forearm; centre: incision for the creation of a subcutaneous pocket; right: positioning of the test material beneath the
skin.
Taking into account the total number of cochlear implan-
tations, the probability of silicone intolerance occurring
is low [51]. In the majority of cases where an allergy is
suspected, the actual problem is more likely to involve a
chronic infection or the formation of bacterial biofilm.
4.2 Formation of connective tissue
around the implant (electrode and
casing)
Although silicone possesses a number of beneficial
properties that make it possible to use it for producing
both flexible electrodes and biocompatible implant
sheaths, it does also have certain disadvantageous
characteristics. These include a relatively strong ability
to induce connective-tissue growth, which can be ob-
served around both the electrode array [52] and the im-
plant casing. Encapsulation of the implant casing can
yield definite advantages, as this provides additional fix-
ation for the implant and makes unwanted displacement
less likely. Formation of connective tissue around the
cochleostomy site is also desirable, as this seals off the
inner ear from the middle ear, which both prevents
perilymphleakingoutoftheinnerearandmakesitharder
for bacteria to ascend from the middle ear into the inner
ear. Within the cochlea, however, the formation of con-
nectivetissueisundesirable,asthissheathofconnective
tissue around the electrodes acts as an insulating layer
that impedes the transfer of charge from the electrode
array to the auditory nerve and thus leads to a postoper-
ative increase in electrical impedance [53]. As stable,
low impedanceis essentialif the electricalstimulationof
the cochlea’s neuronal structures is to be effective and
safe, reduction of connective-tissue growth (or even its
avoidancealtogether)istobesought[54].Intraoperative
administration of steroids could reduce postoperative
tissue response [55]. Various studies have investigated
the reductive effect of a range of steroid preparations on
postoperative fibroblastgrowth in cochlearimplantation,
althoughasolutionoftriamcinoloneacetonide(Kenacort
®
A; 40 mg/ml) has proven highly effective [55]. Measure-
mentsrevealthatpatientsinwhomTriamcinoline(Triam-
hexal 40
®) was used have significantly lower impedance
thanacontrolgroup[33].Along-termstudybyaresearch
team headed by De Ceulaer, in which the effect of one-
timeintracochlearadministrationofsteroidsimmediately
prior to electrode insertion was investigated, revealed a
significantreductioninimpedanceeventwomonthsafter
implantation [56].
4.3 Revision surgery
Clinical observations made in relationto revision surgery
not only show marked formation of connective and scar
tissue around the implant and/or electrode array, but
alsorevealthesheathingofthearraybyconnectivetissue
in the cochlea [2], [35]. In the event that the implant
needs replacing, the electrode can be successfully rein-
sertedinthevastmajorityofcases[57],sothat–despite
the electrode array being enveloped in connective tissue
within the cochlea – the creation and dilatation of a
passage with the electrode of the new implant prove
successful.Rühletal.[58]wereabletodemonstratethat
the outcome of speech understanding tests one year on
from reimplantation was as good as, if not better than,
thatbeforereimplantation.Theliteraturecontainsdescrip-
tions of how, in exceptional cases, the existing electrode
array is held in place within the cochlea by encircling it
with a “wall” of scar tissue or bone [59]. The difficulty in
suchinstancesisthatfurtherattemptstoextractthearray
canonlypartiallyremoveit,witharesidualportionremain-
ingwithinthecochlea[60].Thiscallsforanintraoperative
decisionastowhetheronlyoneelectrode–albeitincom-
pleteandbasallypositioned–canbeinsertedorwhether
a double array can be introduced into the cochlea by
means of two cochleostomies.
4.4 Formation of biofilm
The formation of a biofilm constitutes as as-yet-unsolved
problem in cochlear implantation. Biofilms result when
micro-organismscolonizeboundarysurfaces.Theyconsist
of a thin layer of mucous (i.e. a film) and form primarily
in aqueous or moist systems, either at the aqueous sur-
face or at its interface with a solid.
Cochlear implantation provides a good example of how
these infections can occur as introduced infections that
gainaccessduringsurgery;inprinciple,middle-earinfec-
tions [61] [62], [63] can also spread and thus result in
bacterial colonies that form on components of the im-
plant.Infectionsusuallyaffectthemagneticunit,withthe
electrode less often affected [64]. The silicone surface
of the magnet unit provides bacteria or biofilms with a
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bletoconventional,localorsystemicallyappliedantibiot-
ics. In cochlear implant revision surgery, S. aureus has
often been found [65], [66]. Clinically, the cases in
question are marked by a postoperative healing process
that is initially normal [66]. Over the subsequent weeks
and months, however, recurrent swelling – which often
spontaneously opens – occurs at the implant site or the
mastoid (Figure 9). It tends to discharge only a relatively
smallamountofputridsecretionandthereisoftenstrong
formation of granulation tissue (Figure 10) around the
implant[67].Theimplantsurfaceisusuallyalreadyinfec-
ted in these cases, i.e. a biofilm has already formed on
theimplantsurfacebythistime.Despiteantibiotictherapy
andrinsingwithdisinfectantsolutions,thesebiofilmsare
generally prone to recurrence, so that there is often no
choice but to remove the implant. The implant usually
shows no macroscopic changes in these cases.
Figure 9: Swelling around the implant site in a case where the
implant is chronically infected. Right of picture: spontaneous
perforation of the skin.
Figure 10: Infected cochlear implant with marked formation
of granulation tissue around the implant.
Formation of biofilm is a clinically relevant problem as,
in general, despite several swab samples being taken, it
is not possible to clearly identify the pathogens involved,
and treatment with antibiotics tends to lead to only a
short-term improvement in the situation [68]. Often the
only clinical option in these cases is to remove the im-
plant, leaving the intracochlear electrode in place as an
intracochlear placeholder. The intracochlear electrode is
usuallyunaffectedbytheinfection.Afteraninfection-free
phase of around three months, the reimplantation of the
CI can then be carried out.
Changes in design – in order to avoid dead volume, for
example – can be instrumental in reducing the risk of
infection [69], whereas infections of the middle ear in-
crease the probability that the implant will become infec-
ted [70].
Itisnotalwayseasytomakeaclinicaldistinctionbetween
an infection of the implant or formation of biofilm on the
onehand,andintoleranceoftheimplantmaterials(espe-
cially silicone) on the other; this task occasionally poses
thephysicianadifficultchallenge.Inindividualcases,an
allergy test using test electrode materials, as described
above, may be helpful in resolving this.
Onecomplicationofcochlearimplantationisaheightened
risk of meningitis [71]. As the mechanisms of infection
have not yet, however, been fully clarified, various
mechanisms are discussed in the literature [72]. The CI
reduces the pathogen threshold required to induce
meningitis. The cochleostomy in and of itself, however,
doesnotincreasetheriskofinfection[73].Animalexper-
iments show that the infection occurs only via the direct
route(i.e.themiddleearorinnerear)andnotsystemically
or intraperitoneally [74].
4.5Clinicalrecommendationsforaction
Inviewofthelargenumbersofimplantsandtherelatively
lowratesofinfectionandintolerance,preoperativetesting
with implant materials would not appear justified. How-
ever,itisessentialthatimplantationbeperformedunder
completely sterile conditions so that the implant is not
placed at risk through bacterial contamination, and in
order that reimplantation – which is expensive, as well
as time-consuming for the recipient – can be avoided.
5 Prospects for biomaterials
development in cochlear implants
5.1 The implant of the future –
objectives for new developments in
implants
5.1.1 Clinical requirements
Implantdevelopmentissettopursueanumberofclinical
objectivesinto thefuture.The focuswillbe onenhancing
biomaterialpropertieswithregardtobiocompatibilityand
optimizing the nerve-electrode interface (Figure 11), as
well as on reducing size (especially that of the intracoch-
lear electrode array) and increasing the number of
channels that can be stimulated independently of each
other.
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with inserted perimodiolar cochlear implant electrodes in the
scala tympani, showing the electrode contact surfaces facing
towards the modiolus.
The effectiveness of electrical auditory prostheses must
be optimized to the extent that hearing ability can be
achieved which is as natural as possible. This entails,
among other things, a considerable improvement in
electricalchannelseparationandthusstimulusselectivity,
a reduction in unspecific tissue growth, protection of
neuronalcellsandtheregenerationofneuronaldendrites
that form a cell-specific contact with the electrically con-
ducting electrode material. The current objectives in this
field revolve around the development of new multifunc-
tional electrodes that couple conventional electrode
functions with new bioactive functions. Current ap-
proachestooptimizationtakeintheentireprocesschain
– involving design, material, electrode production and
surface functionalization, and including the individual
adjustments made to each recipient’s own particular
anatomy.
With regard to optimizing the biocompatibility properties
of the cochlear implant’s surface materials which come
intocontactwithbodytissue,thedominantnotionisthat
of preventing the formation of connective tissue around
the intracochlear electrode array, in order to facilitate
improved charge transfer to the auditory nerve at this
point (Figure 5). In addition to the use of completely new
implantmaterials–inparticular,newsiliconesubstances
– the functionalization of conventional silicones also
merits consideration here. This can be achieved by sur-
face structuring (i.e. physical functionalization), by the
binding or release of drugs at the electrode array (i.e.
drugdelivery functionalization),by coatingwithpolymers
(i.e. chemical functionalization), by applying a layer of
cellsinordertoreleasebiologicalsubstances(i.e.biologic-
al functionalization), or by coating with polymers and
signal proteins (i.e. biochemical functionalization)
(Figure 12).
Two goals closely related to these ideas are optimizing
the CI’s nerve-electrode interface by means of releasing
substances into the inner ear (known as local drug deliv-
ery)anddevelopingtheseapproachestothestagewhere
they are technically feasible, as specifically applied to CI
systemscurrentlyinuse(involving,forexample,structural
modification of electrode arrays for fluid release). The
developmentofbiomimeticimplantsrequiresthemtobe
specifically designed with the target tissue in mind.
5.1.2 Biomaterial requirements
If cochlear implant technology is to continue to advance,
especiallyintermsofsurgeryaimedatpreservinghearing
(advances in which include Cochlear Ltd.'s Hybrid L sys-
tem and MedEl GmbH’s Flex EAS), this necessitates the
further miniaturization of the electrode systems in order
to minimize both the insertion trauma caused and the
resulting formation of connective tissue around the in-
tracochlearpartoftheelectrode.Moreover,thematerials
employedshouldmakeitpossibletousealargernumber
of electrode contacts than has previously been the case,
thus allowing better intracochlear frequency resolution.
The technology that might be used here could borrow
fromchiptechnology,withswitchingcircuitssiteddirectly
on the electrode array and active electronic elements on
the intracochlear electrode array.
5.2 New implant materials
5.2.1 Teflon
PTFE (poly(tetrafluoroethylene)), also known as Teflon, is
a thermally and chemically highly stable polymer that is
very hydrophobic. Teflon is already used to a limited ex-
tentincommerciallyavailablecochlearimplants(specific-
ally, for insulating the wires between the implant body
and the electrode contact). In laboratory investigations,
a movable Teflon strip has been used in order to enable
the electrode array to be placed within the cochlea in a
positionclosetothemodiolus[75].Experimentsinvolving
Teflon have also been conducted with a view to using it
for sealing cochleostomy sites, although this technique
did not become established [76], [29].
Among the current applications for Teflon are its use in
vascularprostheses[77],[78],[79]andininvestigations
with a view to repairing defects in the abdominal wall
[80], which have demonstrated its fundamental biocom-
patibility. Extending these applications to CIs would thus
appear conceivable.
5.2.2 Electrically conducting polymers
Promising developments in the material sciences have
demonstrated the technical feasibility of electrically con-
ductingpolymers.Dependingontheirchemicalstructure,
synthetic materials may possess electrically conducting,
semiconducting or isolating properties. It was through
theuseofthesematerialsforelectronicapplicationsthat
the term “polymer electronics” was coined. Whereas
electronic components made of plastic would have been
inconceivable only recently, they are now well on the way
towards becoming reality.
Conductive polymers are usually produced by adding
small quantities of oxidizing agents such as chlorine,
bromine, iodine or arsenic pentafluoride to create the
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polymer matrix. In the process, they acquire electrical
conducting abilities comparable to those of metallic
conductors [81], [82]. The first applications considered
for conductive polymers included batteries and accumu-
lators.Othersemiconductingpolymersareusedprimarily
inthefieldofoptoelectronicsandinphotoniccomponents
[83]. The use of such materials in medical engineering
is, however, problematic in terms of how biocompatible
these substances are at present. Conjugated polymers
inaconductivestateare,almostwithoutexception,insol-
uble, infusible and not very elastic. The metal-like ability
to conduct is inextricably bound up with the solid state
and a crystalline arrangement. One means of producing
modifiable electrically conducting polymers involves the
copolymerization of electrically conducting substances
with conventional polymers, such as polyacetylene in
polyethylene, polystyrol or polypyrrol [84], [85].
The potential benefits of using modified polymers as
electrode materials consist in the improved mechanical
properties of the electrode array and in the scope for
placing a considerably higher number of electrode con-
tacts on the electrode array. This approach could lead to
the electrode having considerably enhanced overall flex-
ibility and thus to further optimization of electrodes that
have the potential to help preserve hearing. However,
polymer-basedimplantsmust,intermsoftheirlong-term
stability and electrical transmission properties, be held
up as the benchmark for conventionalimplantmaterials,
so that immediate clinical application is not yet expected
at the present time.
5.2.3 Polyimides
Evenintheearlyphaseofcochlearimplantdevelopment,
the fundamental biocompatibility of polyimides was
demonstrated. For example, the basic usability of these
materials in the cochlea has been successfully shown
[86]. Polyimidesarepolymers thatarechemicallystable,
electrically insulating and very easy to work with [87],
[88], [89], [90]. Fibroblast growth on polyimide surfaces
is comparable with that on polystyrene surfaces [91].
Polyimidesarealreadyinusetodayforflexibleelectrodes
[92] and as a carrier material for gold wires in the power
supply system for subretinal implants [93]. Furthermore,
the flexibility of these substances enables a smooth
transaction to be facilitated between the electrode (with
its particular mechanical properties) and the tissue, in
order to prevent damage caused by minute movements
of the electrodes (as during neural stimulation, for ex-
ample) [94], [95], [96]. Polyimides thus constitute a
promisingnewprospectforelectrodemanufacture,which
may in the future be incorporated into the production
process for CIs.
5.2.4 Silicon electrodes
Thankstotheveryrapiddevelopmentofchiptechnology,
whichhasinrecentyearsledtoaradicalreductioninthe
size of the componentsused, it is conceivable that these
methods could also be used for multichannel electrode
systems [97]. The use of this technology, i.e. the placing
of active electrode systems on the intracochlear compo-
nentoftheelectrode,couldleadtoautomationandmake
theproductionprocessagooddealfaster,inturnleading
to a reduction in the price of implants. This technology
alsooffersscopeforoptimizingthecouplingbetweenthe
nerve and electrode. It is conceivable that implant func-
tions could be transferred from the implant casing to the
electrode array (i.e. into the cochlea), so that these ad-
vances could ultimately lead to the creation of a purely
intracochlear electrode array that replaces the implant
casing used thus far. This process could draw on diverse
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approachesarebeingpursuedwithaviewtousingactive
electrodesystemsfortheeye.Thisinvolvessilicon-based
photodiode arrays being implanted under the retina; in
these arrays, the stimulating electrodes stimulate the
retinal neurones [98]. A key prerequisite for the applica-
tion of these systems is that they are demonstrably
biocompatible for the inner ear. At the present time, suf-
ficient data relating to the cochlea – such that would in-
dicatethatthistechnologycanberapidlytransferredinto
clinical use – are not available. However, the possibility
ofcost-effectivemassproductionofelectrodes,inpartic-
ular, does make for an interesting prospect with regard
totheintroductionofthistechnologyintotheCImanufac-
turing process.
5.3 Modification of surface properties
5.3.1 Physical functionalization of surfaces
The only way to change biomaterial properties in terms
of biocompatibility is to alter the surface geometry
(Figure 13). The long-term objective of optimized nerve-
electrode interaction can therefore be achieved both by
choosing a new carrier material [99] and through the
structural modification of already known materials and
their surfaces. For silicone, which is chiefly used for the
surface of cochlear implants, the micro- and nanostruc-
turing of the implant surface play a key role here. Investi-
gations using in vitro models have already demonstrated
the crucial effect of microstructuringthe silicone surface
in terms of reducing the growth of connective tissue.
Various laser techniques are used for generating the
surface structures (Figure 14), such as laser ablation,
two-photonpolymerization,laser-inducedmeltingdynam-
ics, lithography and moulding. Nanostructures can thus
specifically influence the hydrophobicity of the surface
and, in turn, material-cell interaction as well.
Altering surface topography by using ultra-short laser
pulsesprovidesanexampleofthephysicalfunctionaliza-
tion of CI materials. In vitro, microstructures of linear
configuration generated by means of laser ablation can
both reduce the growth of connective-tissue cells
(Figure 15) [100] and influence the direction of growth
of neuronal cells [101]. Individual research projects (in-
cluding ventures in close collaboration with industry) are
already underway, the aim of which is to translate into
clinicalapplicationsthetechnologicaladvancesachieved
withCIs(CollaborativeResearchCentre(SFB)599:project
T1).
Anumberofresearchteamshavealsoalreadybeenable
to show that, by structuring the surface of materials on
the nanometric scale, we can considerably influence the
rate at which connective-tissue cells adhere to these
surfaces. The studies by Spatz et al. [102], [103], [104]
can be regarded as groundbreaking in this field; they
demonstrated that structural differences of only a few
nanometres in scale dramatically alter the interactive
behaviour between material and cell.
Figure 13: Schematic representation of physical surface
functionalization: alteration of surface topography.
Figure 14: Example of linear microstructure on silicone,
generated through ablation by ultrashort laser pulses.
Figure 15: Example of physical surface functionalization:
cultivation of cells growing adherently (fibroblasts, duration of
culture: three days) on laser-structured silicone surface
(structural width 10 µm).
The modification of surface structure is thus highly likely
to lead to a change in tissue-implant interaction, despite
the base material used being essentially the same. This
phenomenon has also been demonstrated for various
fields of application other than the cochlea, such as
dental implants [105], [106], [107]. Highly promising
scope for further advances in CI technology is emerging
here.
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The use of chemically modified implant surfaces
(Figure16)andthebiochemicalbondingofactiveagents
to the implant (Figure 17) is another promising approach
by which the development of cochlear implant systems
canbedrivenforward[108].Notonlydoesthisideahave
potential in terms of the basic applicability of implant
coatings for reducing biofilm formation on implants and
electrodes, it is also of particular importance in terms of
optimizing nerve-electrode interaction [109]. In this re-
gard,thisapproachisbasedontheuseofbiodegradable
polymers as an integral part of the CI’s electrode array,
which (following their degradation) lead to biologically
activesubstancesbeingreleasedfromtheelectrodearray
(SFB/Transregio 37: subproject C4).
Figure 16: Schematic representation of biochemical surface
functionalization: binding of signal molecules onto the
electrode.
Figure 17: Schematic representation of chemical surface
functionalization:bindingofpolymerchainsontotheelectrode.
Dental and orthopaedic implants are coated with growth
factors (such as BMP-2) specifically in order to stimulate
the formation of new bone. Various research teams have
investigatedacombinationofBMPsandprostheticjoints
inordertosuccessfullyoptimizetheprocesswherebythe
implantisincorporatedintothesurroundingtissueduring
the healing period [110], [111]. These generally exploit
the principle of adsorption of growth factor proteins at
the surface, so that the release of the substance – and,
ultimately, the specific intended effect of the factor in
question – is achieved over a concentration gradient. Al-
though inductive effects have been described using this
method,disadvantagesarealsoevident.Firstly,relatively
high quantities of the active substance are required in
order to bring about the desired effects [112]. Secondly,
the implants need to be specially pre-treated, which
makes their clinical use more difficult and casts doubt
on the method’s practicability.
Implants with a drug delivery function have already be-
come routine clinical practice in other branches of medi-
cine. A good example are coronary stents, the use of
which has successfully reduced the restenosis rate of
stents [113], [114], [115].
The chemical and biochemical surface functionalization
of CIs is, both for the electrode array and for the implant
casing,a(biomimetic)interventionoptionforwhichdiffer-
ent biological objectives can be pursued. There is good
reason to believe that findings from studies in which
surfaces are coated with drugs can be transferred from
the field of stent technology to that of cochlear implanta-
tion; joint interdisciplinary research projects have thus
been initiated in response to this aspect (SFB 599: sub-
project D2).
5.3.3 Biological functionalization of surfaces
The use of genetically modified cells or stem cells as a
connecting element between the residual nerve cells of
the cochlea and the electrode array is a fascinating pro-
spect – which has already been successfully demon-
strated in animal experiments – in terms of facilitating
initial steps in the regeneration of the inner ear
(Figure 18). Certain animal experiments have been able
to show that genetically altered cells placed on an in-
tracochlear array led to an increase in the survival rate
of spiral ganglion cells (first auditory neuron of the audi-
tory nerve; Figure 19) following deafness. The outcome
of these investigations is encouraging and suggests that
the findings can, in principle, be exploited in order to op-
timize the nerve-electrode interface through biological
functionalization of cochlear implants.
These developments could ultimately lead to the CI sys-
tembeingusedasanintracochleartherapyoption(includ-
ing stem cell therapy). The application of neural stem
cellsisconceivablehere,whichcouldcreateaconnecting
bridge between the residual nerve cells of the cochlea
and the electrode array in order to facilitate enhanced
charge transfer to the auditory nerve. That stem cellsare
generally detectable in the inner ear, and that modified
cells can be used as cochlear stem cells which can be
applied in the inner ear, has already been demonstrated
both in vitro and in animal experiments. A combination
of biological intervention strategies with conventional
approaches to CI therapy offers scope both for improving
the effectiveness of these implants and for drawing up
strategies for regenerative therapy.
Regenerating lost hair cells by transplanting stem cells
intothecochleaorthroughstimulationoflocalstemcells
is a highly ambitious research approach [116], [117],
[118]. However, it will probably not be possible in the
near future to reproduce the complex anatomy of the or-
gan of Corti and the perfect integration of a wide range
of specialized cell types within a very compact space
[119].
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functionalization:bindingofadherentcellsontotheelectrode.
Figure19:Arepresentativeexampleshowingtheconsequences
of deafness in the region of the spiral ganglion. Histological
viewofthespiralganglioncells(SGC)intheRosenthalchannel
(A) when hearing was normal, (B) six weeks after deafening,
withmostoftheSGCshavingdegenerated.Sc.T.scalatympani.
5.4Fundamentalsofdrugdeliveryinthe
inner ear (neurotrophic effects)
Sensorineural hearing loss leads, as a secondary effect,
tothedegenerationofthespiralganglioncells,whichare
the target cells of electrical stimulation by the cochlear
implant. In order to enhance the effectiveness of the CI,
these neurones should be protected from progressive
degeneration. Because of the blood-cochlear barrier
[120], [121], it is not possible for many systematically
applied molecules that potentially have a therapeutic
actionintheinnereartoreachtheirtargetlocation[122].
Theinnerearthusconstitutesacompartmentorchamber
that is unique within the human body, which could be
treated by means of local drug delivery that uses the CI
as a means of access (Figure 20). The potential for this
combined function – i.e. for using the CI electrode array
todeliverdrugs–isobviousandthusoffersconsiderable
possibilities for further advances in the implant system.
Animal experiments have been able to show that the
local application of drugs, combined with electrical stim-
ulation by an implant, can lead to improved outcomes
[123],[124].ByadditionallyusingtheCIasadrugdepot,
substances such as nerve growth factors could prevent
progressive degeneration of the auditory neurones and
thusenhancetheeffectivenessoftheseimplantsforlong-
term use [125], [122]. Steroids and other substances
could also be applied in conjunction with the CI in order,
for example, to minimize or even prevent tissue growth
around the electrode and thus postoperatively maintain
impedance at a low level.
Figure 20: Schematic representationof drug delivery from the
electrode body. Use of the cochlear implant as a means of
access for local drug delivery.
Various research teams have begun exploring these as-
pects and have attempted to modify CIs so that they can
also serve as intracochlear drug depots [126], [127],
[128]. Questions regarding dosage and the potential for
controlling substance release are receiving a great deal
of attention. Active agents must be applied at concentra-
tions that achieve sufficiently high biological effective-
ness. Furthermore, this intervention must not present
the patient with an additional risk. Studies on the effec-
tivenessandthetechnicalfeasibilityoflong-termapplica-
tion of drugs are still at the animal experimental stage.
However, the findings to date are promising and suggest
that this approach could soon see clinical transfer.
5.4.1 Substances
Awiderangeofsubstancesarecurrentlyunderdiscussion
with a view to mediating therapeutic effects on a local
basisintheinnerear.Inadditiontoglucocorticoids(such
as dexamethasone) there are a number of other factors
that play a part, such as antioxidants, neurotrophic
factors, neurotrophines and cytokines.
Glucocorticoids (specifically, triamcinolone) in particular
have been tested in clinical trials as to their effect in re-
ducingelectricalimpedancefollowingcochlearimplanta-
tion [33]. The rationale here consists in reducing growth
of connective tissue around the electrode array following
implantation – an effect which has also been demon-
strated for the period up to initial fitting – in order to fa-
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nerve. Dexamethasone, by contrast, did not lead to a re-
ductioninelectricalimpedancefollowingone-timeadmin-
istration [129], although it does protect against further
hearinglosscausedbyelectrodeinsertiontraumaduring
implantation [130].
Anotherclassofsubstancesthatshowsprotectiveeffects
on spiral ganglion cells in the inner ear are the antioxi-
dants. These can significantly increase the survival of
spiral ganglion cells following deafness [131], [132],
[133]. This effect has its basis in the fact that the forma-
tion of free radicals which arise during ototoxic trauma
can be counteracted by the use of antioxidants such as
trolox(awater-solubleanaloguetovitaminE)andascorbic
acid. This leads both to improvements in the animal
subjects’electricalhearingthresholdandto a significant
increase (compared with a control group) in the number
of surviving spiral ganglion cells [134].
Neurotrophic factors are proteins that act as regulators
of neuronal differentiation. They influence both the
neuronal development of the central and peripheral
nervous system and the development of the auditory
system. In animal experiments, the number of spiral
ganglion cells that survive following deafening increased
significantly (compared with untreated ears) through
cochlearapplicationofnervegrowthfactors[135],[136],
[137],[138],[139],[140].Ithasalsobeendemonstrated
that neurotrophic factors cause nerve structures to re-
elongate,withtheelectrophysiologicallyrelevantstimulus
parameters also showing improvement upon receiving
combinedelectricalstimulation(i.e.electricalstimulation
plus drug application) [141]. In particular, brain-derived
neurotrophic factor (BDNF) appears capable of locally
generating protective effects within the inner ear [142],
[143],[144],[145],[146],[147].However,otherresearch
teams have shown that discontinuing local treatment of
thecochleawithBDNFleadstoaccelerateddegeneration
ofthespiralganglionscellsthatpreviouslywerepreserved
by the factor [148]. It would thus appear expedient to
either apply the factor over a long-term period or to
maintain the protective effect by using other forms of in-
tervention, such as electrical stimulation. The most im-
portant neurotrophic factors (fibroblast growth factor,
neurotrophine, glial cell line-derived neurotrophic factor,
insulin-like growth factor, and transforming growth factor
β) are discussed below, as is their proven effect on spiral
ganglioncells.Invitroandinvivofindingsobtainedusing
these factors will then be discussed in detail.
The fibroblast growth factor (FGF) family, which has 25
members,isinvolvedinnumerousintracellularprocesses
such as cell differentiation, proliferation and survival
[149]. In otological neurogenesis, various FGFs play a
part and mediate their function by specifically binding to
FGF receptors created by alternative splicing.
The family of neurotrophines (NT) is formed from small
secretory proteins including nerve growth factor (NGF),
brain-derivedneurotrophicfactor(BDNF),neurotrophin-3
(NT-3) and neurotrophin-4/5 (NT-4/5). These proteins
are important for neuronal differentiation and neuronal
survival[150],[151].Theymediatetheireffectbymeans
of tyrosine kinase receptors and via the low-affinity p75
neurotrophin receptor [152]. Both NT-3 and BDNF are
expressedbytheinner-earepithelium.Ithasbeenshown
that NT-3 promotes the survival of cochlear neurones,
whereas BDNF also appears to be responsible for the
survival of vestibular neurones [153]. Both the develop-
ment and survival of spiral ganglion cells are influenced
primarilybyNT-3andbyglialcellline-derivedneurotrophic
factor (GDNF) [154].
The GDNF family consists of four members: GDNF,
artemin (ARTN), persephin (PSP) and neurturin (NTN)
[155]. All of these substances activate a common signal
component, the transmembrane tyrosinkinase RET
membraneproteins;theseareanchoredtothemembrane
via glycosylphosphatidyl-inositol, are known as GDNF
family receptor alpha (GFRα) [156], and act as co-recep-
tors for tyrosine kinase RET [157].
Theinsulin-likegrowthfactorsystem(IGF)consistsofthe
growth factors IGF I, II and relaxin, as well as various in-
sulin-like peptides [158]. In mammals, these proteins
bind to specific receptors that are located in the plasma
membrane of the target cells. Studies have shown that
IGIisresponsiblefortheproliferation,differentiationand
survival of neurones in the inner ear [159].
Among the neurotrophic factors, the superfamily of
transforming growth factor-β-(TGF-β) is, with more than
50members,thelargestandmostimportantgroup[160],
[161].Thechiefeffectsofthisgroupofsubstancesrelate
totheirprotectiveinfluencebothonmotorneurones[162]
and (in particular) on the cells of the inner ear. Both pro-
tective effects on spiral ganglion cells [163], [164] and
regenerativeeffectshavebeensuccessfullydemonstrated
here [165], [166]. This class of substances appears par-
ticularly effective when applied shortly before ototoxic
trauma [167], [168], [137].
For cytokines such as erythropoetin (EPO), too, a protect-
ive effect on the spiral ganglion cells of the inner ear has
been demonstrated [169]. Erythropoetin is regarded as
a regulator of the progenitor cells of erythrocytes (see
overview in [170], [171]). However, EPO also helps pro-
motethesurvivalofneuronalcells,asforexamplefollow-
ing injury to the spinal cord [172]. Moreover, in the pres-
ence of EPO the expression and production of BDNF is
increased [173]. In cultivated spiral ganglion cells, al-
though administration of EPO had no observed effect on
cell survival, it was found to increase neurite growth
[174]. The expression of EPO and its receptors in the in-
ner ear has been achieved only recently [175], paving
the way for the first successful intervention in animal ex-
perimentsthatisaimedatprotectinginner-earstructures
[176], [177].
5.4.2 In vitro findings
Cellcultureexperimentsarethefirststepininvestigating
drugs as to their neuroprotective effects on living cells.
The cultivation of isolated spiral ganglion cells in
neonatalratsrepresentsawellestablishedinvitromodel
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[179], [180]. The effects of neurotrophic factors such as
BDNF, GDNF, artemin, meteorin, NGF, NT-3, NT-4/5 and
CNTF on the survival of spiral ganglion cells and neurite
resprouting have been explored in detail. BDNF concen-
trations of 50 and 100 ng/ml are described as those
mosteffective for optimalsurvival of spiralganglioncells
in vitro [179], [181], [182], [183]. Studies have demon-
strated that GDNF has a survival-promoting effect on
neonatal spiral ganglion cells in vitro at a concentration
between 100 pg/ml [139], [184] and 100 ng/ml [183].
Significantly enhanced neuritogenesis, i.e. a marked in-
crease in the length of outgrown spiral ganglion cell
neurites (as compared with an untreated control group),
has been achieved at a concentration between 10 and
50 ng/ml BDNF [180], [185], [186]. Trophic effects of
GDNFapplicationon cultivated spiralganglioncellshave
not yet been described in the literature. These results
suggest that BDNF is a potentially suitable candidate for
mediating neuroprotective effects in the inner ear.
5.4.3 In vivo findings
The majority of animal experimental studies on the
neuroprotective effect of BDNF, GDNF and electrical
stimulation have been performed on guinea pigs [138],
[187], [188], [189]. As considerationson the application
of neurotrophic factors in humans with a view to treating
patientswithsensorineuralhearinglossandsubsequent
degeneration of the spiral ganglion cells, many research
teamsinitiallydeafentheanimalsubjectsusingototoxins
[140], [142], [146] or by exposing them to noise [139].
Kuang [140] has shown – as has Ylikoski et al. [139] –
that 50 ng/ml GDNF, administered directly after deafen-
ing,cansignificantlyprotectthespiralganglioncellsfrom
secondary degeneration. Yagi et al. [142] and Kanzaki
etal.[146]appliedGDNFbymeansofadenoviralvectors
(AdGDNF) and, here too, the results of both research
teamsrevealsignificantprotectionofthenervecellsafter
deafening.EveniftheonsetofGDNFtherapy(100ng/ml)
is delayed until three weeks post-deafening, it still has
potential to protect the spiral ganglion cells [190].
Intracochlearly administered BDNF (50 ng/ml), applied
for 14 days on the seventh day after ototoxic treatment,
brings about significantly improved survival of the spiral
ganglion cells [138]. Gillespie et al. [188] demonstrated
that BDNF, NT-3, NT-4/5 and NGF – each administered
at a concentration of 62.5 µg/ml – can prevent the de-
generation of these cells progressing further after 14
days of deafness. Even where therapy with BDNF + FGF,
NT-3 or CNTF was delayed until one to six weeks after
deafening, this therapy still protected the cells from de-
generation to a significant extent [191], [192], [193],
[194], [145].
Through protecting the spiral ganglion cells from degen-
erating after deafness, and the related provision of a
larger population of these cells for electrical stimulation
via the CI, supportive local treatment with neurotrophic
factors has great potential for enhancing the outcome of
cochlear implantation.
5.5 Technical implementation of
inner-ear drug delivery
5.5.1 Surface drug delivery (via coating)
The release of biologically active substances from the
surface of a cochlear implant electrode array is a prom-
ising approach that is currently being addressed by a di-
verse range of research projects (including Transregio
37:subprojectC4).Thebasicapproachhasalreadybeen
outlined in section 5.3.2.
5.5.2 Fluid-based drug delivery (via pump)
Figure 21: Model investigation of electrode prototypes for
delivery of fluids within the cochlea. Shown here: release of a
dye at both the tip and side of the electrode array as a means
of intracochlear fluid application.
Figure 22: Schematic structure of a cochlear implant with
integral micropump (MedEl GmbH) showing a septum port
between the implantable pump (i.e. the circular structure on
the right) and the implant (left).
Fluid-based delivery of biologically active substances by
means of a cochlear implant can be made possible, for
example,byusinganimplantablepumpthatisconnected
to the CI system. A number of individual electrode proto-
types have already been produced for this purpose
(Figure 21) and have demonstrated the basic feasibility
of such an approach [127], [128]. In addition to the
challenge of creating a usable system that is clinically
safe, an implantable, preferably refillable pump that al-
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this approach is to become reality. The production of in-
dividual prototypes (Figure 22) has already paved the
way for this.
Underlying investigations into fluid movements in the
natural cochlear and the distribution pattern of sub-
stances applied into the cochlea have been carried out
by the team headed by A. Salt [195], [196]. This group
has, for example, developed a technique for sequential
sampling of perilymph from the scala tympani [197].
Computermodelshavealsobeendevelopedthatallowed
simulation of the distribution of the substances applied
into the cochlea [198], [199].
Animal experimental studies suggest that pump rates of
around0.5µlperhourcouldbeused[143],[200].These
lowvolumesposeaconsiderablechallengeintermsboth
of fluid flow within the cochlea and the positioning of the
possible openings for drug delivery, as well as the accur-
acy of the implantable pump [201]. Here, too, initial in-
vestigations confirm the basic technical feasibility of this
approach and thus lay the foundation for further upcom-
ing clinical application studies.
5.5.3 Anti-inflammatory nanoparticles
A major focus in nanobiotechnology is antimicrobial sur-
facecoatingofimplants.Insomestudies,itwasprimarily
nano-silver that proved more effective than other mater-
ialsasananti-inflammatoryagentandinfectionsuppress-
ant [202], since it – in addition to the antibiotic effect –
also has lower toxicity. Work on endoprosthetic hip joints
has shown that reduced infection rates, enhanced
biocompatibility and a reasonable useful life for the im-
plantsarepossible[203].Furthermore,theperioperative
use of antibiotics can be reduced in this way, so that sil-
ver-coated implants are characterized overall by a highly
favourable cost-benefit ratio. The application of these
techniques for cochlear implants thus appears, in prin-
ciple, to be promising.
5.5.4 Nanoparticles and cochlear implants
The miniaturization of drug carriers down to nanoscale
level has led to strategies being devised whose aim is –
byusingnanoparticles–toallowcochlearimplant-based
release of drugs for local therapy of the inner ear. Nano-
particles, functioning as non-viral vectors of biogenic
agents (e.g. genes, neuroptrophic factors and steroid
sequences), protected from the effects of the body’s
metabolism, are to be transported specifically to the de-
sired target location and time-released. Integrating a
minute (nanoscale) drug depot into a CI could for ex-
ample, under this approach, lead to targeted release of
neurotrophic factors and eventually to an improvement
in nerve-electrode interaction.
The uptake of nanoparticles has already been demon-
strated in the inner ear [204], as has the fundamental
biocompatibility of the particles used in terms of pre-
servinginner-earstructuresandtheirfunction[205].That
nanoparticles can be used in the inner ear has thus
already been evidenced, so that here – by combining the
fluid-based application of substances and nanoparticle
technology – the use of modified biomaterials for CIs is
opening up a new field for inner-ear intervention.
6 Outlook
By taking materials and technologies that already exist
in the field of cochlearimplantationand combiningthem
withnewapproachesaimedatoptimizingthebiomaterials
used,awiderangeofpossibilitiesisopenedupforfurther
advances in these implants. In particular, the fact that
scope is being incorporated for surface functionalization
of conventional materials, for introducing new implant
materialsandalsofordevelopingstrategiesonlocaldrug
delivery, indicates the prospects that are emerging for
additional improvements in biocompatibility and for op-
timizing the nerve-electrode interface. Both approaches
could thus, in the long term, lead to a marked functional
improvement in the implant systems currently in use.
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